Delcath Systems (DCTH) vs Sight Sciences (SGHT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sight Sciences (SGHT) has outperformed Delcath Systems (DCTH) over the past year, gaining 163.0% versus a gain of 41.2%. Over five years, DCTH leads with a +63.2% price change compared with -58.7% for SGHT. Delcath Systems is the larger company by market cap ($533.0 million vs $489.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCTH | SGHT |
|---|---|---|
| Share price | $15.36 | $8.89 |
| Market cap | $532.97M | $489.73M |
| 1-day change | +2.13% | +4.96% |
| YTD return | +52.08% | +12.11% |
| 1-year return | +41.18% | +163.02% |
| 5-year return | +63.23% | -58.65% |
| Forward P/E | 341.33 | — |
| EPS (TTM) | $0.01 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.42 | $9.71 |
| 52-week low | $8.12 | $3.22 |
| Distance from 52-week high | -11.83% | -8.47% |
| Analyst consensus | none | buy |
| Avg. price target upside | +56.25% | +5.74% |
| Average volume | 479.73K | 260.44K |
| Shares outstanding | 34.70M | 55.09M |
| Employees | 156 | 186 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SGHT has outperformed DCTH by 121.8 percentage points over the past year.
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Health Care · Medical/Dental Instruments · 156 employees
About Sight Sciences
SGHT stock →Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye.
Health Care · Medical/Dental Instruments · 186 employees
DCTH vs SGHT FAQ
Which is bigger, Delcath Systems or Sight Sciences?
Delcath Systems (DCTH) is larger, with a market capitalization of $532.97M compared with $489.73M for Sight Sciences (SGHT).
Which stock has performed better over the past year, DCTH or SGHT?
SGHT returned +163.02% over the past 12 months, compared with +41.18% for DCTH (price return, excluding dividends). Past performance does not predict future results.
Are Delcath Systems and Sight Sciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.